The U.S. Food and Drug Administration put an import alert on medicine produced at the Mohali factory belonging to India-base drugmaker Ranbaxy, which is based in Mumbai and has its U.S. headquarters in Princeton.
The notice is dated Sept. 13 and is posted on the FDA website, with a link here.
The notice means the products can be seized by U.S. authorities without examination. The alert was posted because of concerns about manufacturing problems at the facility.
Ranbaxy is the largest India-based company and focuses on generic products in the United States.